Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Files Subcutaneous Leqembi Autoinjector in Japan
December 1, 2025
- MSD to End Gardasil Sales in Japan as Use Shifts to 9-Valent HPV Shot
December 1, 2025
- Insmed Japan to Double Sales Force with Brensocatib Launch on the Horizon
November 28, 2025
- Chugai’s Market Cap Tops 14 Trillion Yen, Eyes Further Growth through “Co-Creation”: CEO
November 28, 2025
- Teijin to Receive US$5 Million Milestone as Narcolepsy Drug Enters European PI
November 28, 2025
- Izervay, Vorzzz, Dormicum Syrup Now Available in Japan
November 28, 2025
- Meiji Seeks Label Expansion for Laserphyrin in Cervical Intraepithelial Neoplasia
November 28, 2025
- Jardiance Tops 7 Categories in October Promotion Rankings: Intage
November 28, 2025
- Otsuka’s Sibeprenlimab Earns FDA’s Accelerated Nod for IgAN
November 27, 2025
- Japan PIII Trial Begins for Kagoshima University Spinout’s Oncolytic Virus
November 27, 2025
- Mochida, Ayumi Curb Shipments of Humira Biosimilar 40 mg amid Surging Orders
November 27, 2025
- Toray Out-Licenses Peripheral Neuropathy Drug to Sanodyne
November 27, 2025
- Renalys’ IgAN Drug Nets Positive PIII Data, 2026 Japan Filing on Track
November 27, 2025
- Rolling Submission for Leqembi SC Starting Dose Completed in US
November 27, 2025
- Taisho Touts Low Next-Day Carryover for New Insomnia Drug Vorzzz
November 26, 2025
- Alfresa/Mycenax-Led Biosimilar JV to Be Named Alfenax Biologics
November 26, 2025
- Chugai Targets Japan Filing in 2026 for Ranibizumab Eye Implant
November 26, 2025
- Allergan Japan Files TrenibotE for Glabellar Lines Treatment
November 26, 2025
- Taiho Begins Rolling US NDA Submission for Zipalertinib
November 26, 2025
- Padcev/Keytruda Wins US Nod for Perioperative Bladder Cancer Use
November 26, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…